The invention relates to a method for preparation of a sample (10) of a formulation (11) for subsequent endotoxin determination, the formulation (11) suspected of comprising an endotoxin, the formulation (11) preferentially being a pharmaceutical formulation. The method comprises the following steps: application of the sample (10) to an endotoxin-free centrifugation column (2) containing a size exclusion chromatography matrix (5) that has been equilibrated with a suitable equilibration buffer (6) and elution of a flow through (15) of the sample by centrifugation, which flow through (15) can then be used for endotoxin determination. The equilibration buffer (6) is selected according to a subsequently used method of endotoxin determination, the equilibration buffer (6) only containing components not interfering with subsequently used method of endotoxin determination. Furthermore, the invention relates to a kit (20) for preparation of a sample (10).

A mixed mode affinity chromatography carrier includes a substrate, a hydrophilic polymer, an antibody-binding cyclic peptide, and a cation exchange group.

A mixed mode affinity chromatography carrier includes a substrate, a hydrophilic polymer, an antibody-binding cyclic peptide, and a cation exchange group.

A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.

A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.

The present invention provides that powder is mainly constituted from secondary particles of hydroxyapatite. The secondary particles are obtained by drying a slurry containing primary particles of hydroxyapatite and aggregates thereof and granulating the primary particles and the aggregates. A bulk density of the powder is 0.65 g/mL or more and a specific surface area of the secondary particles is 70 m.sup.2/g or more. The powder of the present invention has high strength and is capable of exhibiting superior adsorption capability when it is used for an adsorbent an adsorption apparatus has.

The present invention provides that powder is mainly constituted from secondary particles of hydroxyapatite. The secondary particles are obtained by drying a slurry containing primary particles of hydroxyapatite and aggregates thereof and granulating the primary particles and the aggregates. A bulk density of the powder is 0.65 g/mL or more and a specific surface area of the secondary particles is 70 m.sup.2/g or more. The powder of the present invention has high strength and is capable of exhibiting superior adsorption capability when it is used for an adsorbent an adsorption apparatus has.

The measurement of glutaraldehyde-based biocides in seawater without the use of a derivatization agent. The measurement of glutaraldehyde-based biocides in seawater may be performed without additional components to reduce background interferences. The concentration of a glutaraldehyde-based biocides in a seawater sample is determined using reversed phase liquid chromatography and a gradient mobile phase of acetonitrile and deionized water. Systems for determining the concentration of glutaraldehyde-based biocide in a seawater injection system are also provided.

The measurement of glutaraldehyde-based biocides in seawater without the use of a derivatization agent. The measurement of glutaraldehyde-based biocides in seawater may be performed without additional components to reduce background interferences. The concentration of a glutaraldehyde-based biocides in a seawater sample is determined using reversed phase liquid chromatography and a gradient mobile phase of acetonitrile and deionized water. Systems for determining the concentration of glutaraldehyde-based biocide in a seawater injection system are also provided.

A device for separating one or more molecules of interest in a liquid specimen including a monolithic body defining a fractionation column. The column includes an inlet opening at a proximal end of the fractionation column; an outlet opening at a distal, opposite end of the fractionation column; a solid phase chamber positioned between the inlet opening and the outlet opening; a specimen introduction area adjacent a proximal end of the solid phase chamber; an analyte exit area adjacent a distal end of the solid phase chamber; an inlet chamber adjacent the inlet opening that tapers into the specimen introduction area; and an outlet chamber that extends from the analyte exit area to the outlet opening. A metered amount of solid phase packed within the solid phase chamber between a first porous frit and a second porous frit of the solid phase chamber.